Prof. Frank Griesinger is Director of the Department of Hematology and Oncology at the Pius-Hospital, Oldenburg, Germany; and Professor of Internal Medicine and Oncology at the University of Oldenburg, Germany.
With over 25 years’ experience in the study and treatment of lung cancer (including NSCLC), his research currently focuses on treatment of molecular sub-groups of lung cancer; with specialisms including Phase II and Phase III clinical trials in the neoadjuvant setting. He is also highly involved in the introduction of molecular stratified treatments for lung cancer in Germany.
Prof. Griesinger has co-authored over 100 international, peer-reviewed papers; and is the First Author of guidelines of the German Society of Hematology and Oncology for the treatment of non-small-cell lung cancer. He is also a member of the: American Society of Clinical Oncology (ASCO); American Society of Hemotology (ASH); International Association for the Study of Lung Cancer (IASLC); and steering committee of the Thoracic Oncology Group of the AIO in Germany.
EM-58642; Date of preparation: April 2021